SCHEMBL5629698

SCHEMBL5629698

COc1ccccc1-c1ccc(S(N)(=O)=O)c(N)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.54
PTPN1 P18031 1/20 0.54
PTGS2 P35354 3/20 0.49
PTGS1 P23219 2/20 0.49
PKM P14618 1/20 0.47
BRD4 O60885 2/20 0.47
DHFR P00374 1/20 0.46
MAP4K4 O95819 1/20 0.46
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45
SCN9A Q15858 1/20 0.45
CHEK1 O14757 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CYP2C9 P11712 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5953394 0.79 PTPRC (0.56) PTPRCPTPN1PTGS1DHFRMAP4K4
SCHEMBL29655117 0.79 PTPRC (0.56) PTPRCPTPN1PTGS1DHFRMAP4K4
SCHEMBL29655234 0.79 PTPRC (0.56) PTPRCPTPN1PTGS1DHFRMAP4K4
SCHEMBL5625109 0.78 PKM (0.46) PTPRCPTPN1PTGS2PTGS1PKM
SCHEMBL3879534 0.76 PTGS2 (0.67) PTPRCPTPN1PTGS2PTGS1CA2
SCHEMBL3380244 0.76 HTR6 (0.49) PTPRCPTPN1PTGS2PTGS1PKM
SCHEMBL27530021 0.75 PTGES2 (0.54) BRD4MAP4K4CA2CA9CA12
SCHEMBL28890398 0.74 HTR6 (0.47) PTPRCPTPN1PTGS2PTGS1PKM
SCHEMBL9045763 0.73 PTGS2 (0.52) PTPRCPTPN1PTGS2PTGS1BRD4
SCHEMBL13205873 0.73 DHODH (0.54) PTPRCPTPN1DHFRMAP4K4EDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 US disclosed
US-6943159-B1 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2005-09-13 US disclosed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 US disclosed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 EP disclosed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 PTPRC 2651/4885PTPN1 3461/4885PTGS2 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.